Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma

Yonsei Medical Journal

Volumn 54, Issue 3, 2013, Pages 643-649

  Lee, Kyong Joo ^a   Yi, Seung Woo ^a   Chung, Moon Jae ^a   Park, Seung Woo ^a   Song, Si Young ^a   Chung, Jae Bock ^a   Park, Jeong Youp ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

CA 19 9; Carcinoembryonic antigen; Pancreas adenocarcinoma; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CHEMILUMINESCENCE IMMUNOASSAY; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREAS ADENOCARCINOMA; TUMOR VOLUME;

CA 19-9; CARCINOEMBRYONIC ANTIGEN; PANCREAS ADENOCARCINOMA; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84875901745     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.3.643     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. Winek T, Hamre D, Mozell E, Vetto RM. Prognostic factors for survival after pancreaticoduodenectomy for malignant disease. Am J Surg 1990;159:454-456.
3. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111.
4. Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum bio-markers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011;137:375-389.
5. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921-929.
6. Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Can preoperative CA 19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 2009;24:1869-1875.
7. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
8. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-138.
9. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73:1148-1154.
10. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specifc antigen in serum of patients with colon carcinoma. Science 1981;212:53-55.
11. Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 2008;95:453-459.
12. Mehta J, Prabhu R, Eshpuniyani P, Kantharia C, Supe A. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol 2010;31:190-194.
13. Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26:5918-5922.
14. Gold P, Freedman SO. Demonstration of tumor-specifc antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-462.
15. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9:735-740.
16. Kalser MH, Barkin JS, Redlhammer D, Heal A. Circulating car-cinoembryonic antigen in pancreatic carcinoma. Cancer 1978;42(3 Suppl):1468-1471.
17. Taylor OM, Cooper EH, Benson EA, McMahon MJ. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas. Eur J Surg Oncol 1992;18: 508-513.
18. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-5503.
19. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-270.
20. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA 19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31: 164-169.
21. Peterli R, Meyer-Wyss B, Herzog U, Tondelli P. [CA 19-9 has no value as a tumor marker in obstructive jaundice]. Schweiz Med Wochenschr 1999;129:77-79.
22. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010;31:171-180.
23. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205-211.
24. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-143.
25. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stan-ners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-334.
26. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008;14:4843-4849.
27. Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011;11:1409-1418.